[Cost-effectiveness of treatment of type 2 diabetes mellitus in México].

Revista médica del Instituto Mexicano del Seguro Social Pub Date : 2023-03-01

Diana L Pérez-Lozano, Víctor Manuel Camarillo-Nava, Tarsila Elizabeth Juárez-Zepeda, José Elpidio Andrade-Pineda, Danae Pérez-López, Jorge Armando Reyes-Pacheco, Zuley Margarita Lucho-Gutiérrez, Liliana Carmona-Aparicio

{"title":"[Cost-effectiveness of treatment of type 2 diabetes mellitus in México].","authors":"Diana L Pérez-Lozano, Víctor Manuel Camarillo-Nava, Tarsila Elizabeth Juárez-Zepeda, José Elpidio Andrade-Pineda, Danae Pérez-López, Jorge Armando Reyes-Pacheco, Zuley Margarita Lucho-Gutiérrez, Liliana Carmona-Aparicio","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Type 2 Diabetes Mellitus (DM2) is a public health and socioeconomic problem, generating direct medical costs for its treatment.Objective: To analyze the cost-effectiveness of monotherapy and bitherapy treatments in patients with DM2.Methods: Cost-effectiveness, observational, ambispective, cross-sectional and analytical analysis of files in a first level medical unit. The data in the cost matrix was executed with the Office Excel 2010 program; the most prescribed drug was identified and compared with monotherapy and bitherapy.Results: The annual direct medical costs of the total population were drug cost $118,561.70MN, hospitalization cost $243,756.00MN, consultation cost $327,414.00MN and clinical trial cost $2416.79MN, obtaining an annual total of $692,148.58MN. metformin was the most indicated in monotherapy (88.4%) and as standard therapy it has higher cost-effectiveness compared to glibenclamide. In bitherapy it was metformin/glibenclamide (35.7%) versus the therapeutics of metformin/NPH insulin, metformin/insulin glargine and metformin/dapagliflozin, which had a better cost-effective result, with an incremental cost effectiveness of -$1,128,428.50MN, -$34,365.00 MN, -$119,848.97MN respectively.Conclusions: Metformin presented a better cost-effectiveness ratio in monotherapy, while in bitherapy it was the metformin/NPH insulin association.","PeriodicalId":21419,"journal":{"name":"Revista médica del Instituto Mexicano del Seguro Social","volume":"61 2","pages":"172-180"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3a/42/04435117-61-2-172.PMC10396055.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista médica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 2 Diabetes Mellitus (DM2) is a public health and socioeconomic problem, generating direct medical costs for its treatment.

Objective: To analyze the cost-effectiveness of monotherapy and bitherapy treatments in patients with DM2.

Methods: Cost-effectiveness, observational, ambispective, cross-sectional and analytical analysis of files in a first level medical unit. The data in the cost matrix was executed with the Office Excel 2010 program; the most prescribed drug was identified and compared with monotherapy and bitherapy.

Results: The annual direct medical costs of the total population were drug cost $118,561.70MN, hospitalization cost $243,756.00MN, consultation cost $327,414.00MN and clinical trial cost $2416.79MN, obtaining an annual total of $692,148.58MN. metformin was the most indicated in monotherapy (88.4%) and as standard therapy it has higher cost-effectiveness compared to glibenclamide. In bitherapy it was metformin/glibenclamide (35.7%) versus the therapeutics of metformin/NPH insulin, metformin/insulin glargine and metformin/dapagliflozin, which had a better cost-effective result, with an incremental cost effectiveness of -$1,128,428.50MN, -$34,365.00 MN, -$119,848.97MN respectively.

Conclusions: Metformin presented a better cost-effectiveness ratio in monotherapy, while in bitherapy it was the metformin/NPH insulin association.

Abstract Image

本刊更多论文

[墨西哥治疗2型糖尿病的成本效益]。

背景：2型糖尿病是一个公共卫生和社会经济问题，其治疗产生了直接的医疗费用。目的：分析DM2患者单药和双药治疗的成本效益。方法：一级医疗单位档案的成本效益、观察性、前瞻性、横断面和分析分析。成本矩阵中的数据使用Office Excel 2010程序执行；确定了处方最多的药物，并与单药治疗和双药治疗进行了比较。结果：总人群的年直接医疗费用为药物费用118561.70MN，住院费用243756.00MN，咨询费用327414.00MN，临床试验费用2416.79MN，年总费用692148.58MN。二甲双胍是单药治疗中最适用的药物（88.4%），作为标准治疗，它比格列本脲具有更高的成本效益。在比特疗法中，二甲双胍/格列本脲（35.7%）与二甲双胍/NPH胰岛素、二甲双胍/甘精胰岛素和二甲双胍/达格列嗪的治疗方法相比，具有更好的成本效益，其成本效益分别为-111842850MN、-3436500MN和119848.97MN。结论：二甲双胍在单药治疗中具有更好的成本效益比，而在双药治疗中则与二甲双胍/NPH胰岛素相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista médica del Instituto Mexicano del Seguro Social

自引率

0.00%

发文量